H
Hirotsu Bio Science
Developed N-Nose, a non-invasive cancer screening product using nematode worms to detect early-stage cancers through urine samples
About Hirotsu Bio Science
Hirotsu Bio Science is a pioneering biotechnology company specializing in cancer diagnostics and treatment. The company leverages advanced nematode-based technology to detect cancer at early stages, providing a significant advantage in personalized treatment plans. Operating primarily in the healthcare and biotechnology sectors, Hirotsu Bio Science serves medical institutions, research organizations, and healthcare providers. The company's business model revolves around the development and commercialization of diagnostic tests, particularly the N-NOSE test, which uses nematodes to detect cancer biomarkers in urine samples. Revenue is generated through the sale of these diagnostic tests and related services.
Read full description
Hirotsu Bio Science's market includes both domestic and international clients, with a focus on expanding its reach globally. The company aims to revolutionize cancer diagnostics by offering a non-invasive, accurate, and cost-effective solution for early cancer detection. By integrating cutting-edge research with practical applications, Hirotsu Bio Science is positioned to make a significant impact on the healthcare industry.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Tokyo, Japan
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 69.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2024 | $0 | — | Eastern Car Liner | ↗ |
| LATE VCOther financing | Dec 2023 | $0 | — | Dynamite Brother Senshidkate · NPH Holdings | — |
Growth signals
Latest recorded traffic for Hirotsu Bio Science is 15K monthly website visits, up 0% over the last three months. Hirotsu Bio Science's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Shinkin Capital- TGTokyo Kiraboshi Financial Group
Free bank Capital
Iyogin Capital
Toppan Forms
Nippon Broadcasting System
Ichinen Holdings
Sompo Holdings
SBI Investment
Future Venture Capital
MS&AD
Series B and later3 investors entered at this stage
Dynamite Brother Senshidkate- NHNPH Holdings
Eastern Car Liner
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hirotsu Bio Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hirotsu Bio Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.